AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8735854 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8735854 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray (FPANS) 200 micrograms once daily for 1 year
Number of subjects: 0
Study 1720846 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril 10 mg
Number of subjects: 340
Study 1720846 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril 20 mg
Number of subjects: 340
Study 1720846 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 340
Study 6816333 — intervention group
Group type: EXPERIMENTAL
Intervention: Home blood pressure recording
Number of subjects: 57
Study 6816333 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinic blood pressure recording
Number of subjects: 57
Study 30314712 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised duration of elastic compression therapy
Number of subjects: 865
Study 30314712 — intervention group
Group type: COMPARATOR
Intervention: Standard duration of elastic compression therapy
Number of subjects: 865
Study 28372313 — intervention group
Group type: EXPERIMENTAL
Intervention: 3‐point bending cervical extension traction
Number of subjects: 30
Study 28372313 — intervention group
Group type: COMPARATOR
Intervention: Stretching exercises and infrared
Number of subjects: 30
Study 25643766 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-remifentanil combination
Number of subjects: 66
Study 25643766 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine-remifentanil combination
Number of subjects: 66
Study 25643766 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 66
Study 23258191 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually tailored physical and daily activities
Number of subjects: 322
Study 23258191 — intervention group
Group type: COMPARATOR
Intervention: Ordinary care
Number of subjects: 322
Study 23258191 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually tailored physical and daily activities (more than 150 min/week)
Number of subjects: 322
Study 23258191 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually tailored physical and daily activities (more than 10 weeks)
Number of subjects: 322
Study 22006695 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting body orientation
Number of subjects: 21
Study 22006695 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine body orientation
Number of subjects: 21
Study 19143854 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin 5 mg once daily (SOL5)
Number of subjects: 357
Study 19143854 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin 10 mg once daily (SOL10)
Number of subjects: 357
Study 19143854 — intervention group
Group type: COMPARATOR
Intervention: Tolterodine immediate release 2 mg twice daily (TOL4)
Number of subjects: 357
Study 17046466 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-thioguanine
Number of subjects: 1498
Study 17046466 — intervention group
Group type: COMPARATOR
Intervention: 6-mercaptopurine
Number of subjects: 1498
Study 15631608 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion (300 mg/day for 10 weeks)
Number of subjects: 497
Study 15631608 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 497
Study 11762658 — intervention group
Group type: EXPERIMENTAL
Intervention: Desogestrel 75 microg/day
Number of subjects: 83
Study 11762658 — intervention group
Group type: COMPARATOR
Intervention: Copper-bearing IUCD
Number of subjects: 83
Study 10322871 — intervention group
Group type: EXPERIMENTAL
Intervention: Buyang Huanwu Decoction (BYHWD)
Number of subjects: 60
Study 10322871 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (control)
Number of subjects: 60
Study 7970999 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin 400 micrograms
Number of subjects: 25
Study 7970999 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin
Number of subjects: 25
Study 7970999 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 3679623 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg naftidrofuryl
Number of subjects: 10
Study 3679623 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 29871368 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mL ESI
Number of subjects: 60
Study 29871368 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mL ESI
Number of subjects: 60
Study 29871368 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mL ESI
Number of subjects: 60
Study 29871368 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (4 mL, 6 mL, 8 mL)
Number of subjects: 60
Study 29071947 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture stimulation of the sciatic nerve trunk
Number of subjects: 60
Study 29071947 — intervention group
Group type: COMPARATOR
Intervention: Simple routine acupuncture (Control)
Number of subjects: 60
Study 24846036 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (education and advice, manual therapy, home exercise, gait aid if appropriate)
Number of subjects: 102
Study 24846036 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (inactive ultrasound and inert gel)
Number of subjects: 102
Study 24846036 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 102
Study 24846036 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 102
Study 22551785 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib 600 mg b.i.d.
Number of subjects: 44
Study 22551785 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib (dose-escalated to 600 mg b.i.d. and 800 mg b.i.d.)
Number of subjects: 44
Study 22551785 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib (dose-escalated)
Number of subjects: 44
Study 19448128 — intervention group
Group type: EXPERIMENTAL
Intervention: NIDCAP (Newborn Individualized Developmental Care and Assessment Program)
Number of subjects: 38
Study 19448128 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 38
Study 18798437 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole (400 mg) and clindamycin (100 mg) in vaginal tablets
Number of subjects: 105
Study 18798437 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin alone (600 mg/daily) orally for six days
Number of subjects: 105
Study 15860388 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised cycle ergometer exercise training (ET) at 60% of peak VO2, three times a week, 60 min each session, for 8 weeks
Number of subjects: 59
Study 15860388 — intervention group
Group type: COMPARATOR
Intervention: Control group (not exercised)
Number of subjects: 59
Study 12504698 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03%
Number of subjects: 269
Study 12504698 — intervention group
Group type: COMPARATOR
Intervention: Latanoprost 0.005%
Number of subjects: 269
Study 10929164 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensional preoperative intervention including exercise training twice per week, education and reinforcement, and monthly nurse-initiated telephone calls.
Number of subjects: 249
Study 10929164 — intervention group
Group type: COMPARATOR
Intervention: Control group (no preoperative intervention).
Number of subjects: 249
Study 8694317 — intervention group
Group type: EXPERIMENTAL
Intervention: remifentanil 0.5 micrograms/kg
Number of subjects: 26
Study 8694317 — intervention group
Group type: EXPERIMENTAL
Intervention: remifentanil 1.0 micrograms/kg
Number of subjects: 26
Study 8694317 — intervention group
Group type: EXPERIMENTAL
Intervention: alfentanil 10 micrograms/kg
Number of subjects: 26
Study 8694317 — intervention group
Group type: EXPERIMENTAL
Intervention: alfentanil 20 micrograms/kg
Number of subjects: 26
Study 8694317 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 26
Study 1563371 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling at 80 W for 12 min
Number of subjects: 10
Study 1563371 — intervention group
Group type: COMPARATOR
Intervention: Passive sitting (control)
Number of subjects: 10
Study 3781322 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone 10 mg iv
Number of subjects: 30
Study 3781322 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 3781322 — intervention group
Group type: COMPARATOR
Intervention: Normal gastric emptying
Number of subjects: 30
Study 3781322 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 30
Study 28726273 — intervention group
Group type: EXPERIMENTAL
Intervention: NIF+EGCG
Number of subjects: 350
Study 28726273 — intervention group
Group type: COMPARATOR
Intervention: NIF+placebo
Number of subjects: 350
Study 26947059 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised-facility multicomponent exercise program (MEP), 65 minutes, 5 days/week, for 24 weeks
Number of subjects: 100
Study 26947059 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised-facility multicomponent exercise program (MEP)
Number of subjects: 100
Study 24014042 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for anorexia nervosa (CBT-AN)
Number of subjects: 63
Study 24014042 — intervention group
Group type: COMPARATOR
Intervention: Specialist Supportive Clinical Management
Number of subjects: 63
Study 21510830 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg
Number of subjects: 120
Study 21510830 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg
Number of subjects: 120
Study 21510830 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg + Aliskiren 300 mg
Number of subjects: 120
Study 19723313 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT) by a specialised physiotherapist for 9-18 sessions over 6 months
Number of subjects: 400
Study 19723313 — intervention group
Group type: COMPARATOR
Intervention: Tension-free vaginal tape (TVT) surgery
Number of subjects: 400
Study 17717214 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I: ETT positioned by auscultation and withdrawn 2 cm
Number of subjects: 107
Study 17717214 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II: ETT positioned with prescribed marks at vocal cords
Number of subjects: 107
Study 17717214 — intervention group
Group type: EXPERIMENTAL
Intervention: Group III: ETT positioned by palpating tip at suprasternal notch
Number of subjects: 107
Study 15065835 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistive inspiratory manoeuvres (RIM) at 80% of maximum sustained inspiratory pressure
Number of subjects: 20
Study 15065835 — intervention group
Group type: COMPARATOR
Intervention: Standardised physiotherapy (SP) for 30 min
Number of subjects: 20
Study 11481401 — intervention group
Group type: EXPERIMENTAL
Intervention: apoLFbuf (4.5 g bovine LF with gastric pH buffer)
Number of subjects: 12
Study 11481401 — intervention group
Group type: EXPERIMENTAL
Intervention: apoLF (4.5 g bovine LF without buffer)
Number of subjects: 12
Study 11481401 — intervention group
Group type: EXPERIMENTAL
Intervention: holoLF (iron-saturated LF)
Number of subjects: 12
Study 9669008 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine-fentanyl (0.125% bupivacaine with 0.005 mg/ml fentanyl)
Number of subjects: 30
Study 9669008 — intervention group
Group type: COMPARATOR
Intervention: bupivacaine-morphine (0.125% bupivacaine with 0.05 mg/ml morphine)
Number of subjects: 30
Study 9669008 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine-fentanyl
Number of subjects: 30
Study 9669008 — intervention group
Group type: COMPARATOR
Intervention: bupivacaine-morphine
Number of subjects: 30
Study 7508689 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Number of subjects: 0
Study 7508689 — intervention group
Group type: COMPARATOR
Intervention: Control group (not treated with hydroxyurea)
Number of subjects: 0
Study 3175546 — intervention group
Group type: EXPERIMENTAL
Intervention: Packages containing suppositories
Number of subjects: 94
Study 3175546 — intervention group
Group type: COMPARATOR
Intervention: Packages containing capsules or tablets
Number of subjects: 94
Study 3175546 — intervention group
Group type: EXPERIMENTAL
Intervention: Six different packages for suppositories
Number of subjects: 94
Study 3175546 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation of six packages by patients
Number of subjects: 94
Study 31188691 — intervention group
Group type: EXPERIMENTAL
Intervention: Bench Press (BP)
Number of subjects: 15
Study 31188691 — intervention group
Group type: EXPERIMENTAL
Intervention: Half Squat (HS)
Number of subjects: 15
Study 31188691 — intervention group
Group type: EXPERIMENTAL
Intervention: Bench Press plus Half Squat (BP plus HS)
Number of subjects: 15
Study 31188691 — intervention group
Group type: COMPARATOR
Intervention: Control trial
Number of subjects: 15
Study 28363686 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pathways-based intervention
Number of subjects: 15141
Study 28363686 — intervention group
Group type: COMPARATOR
Intervention: Control (standard care)
Number of subjects: 15141
Study 25166623 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine evaluation of gastric residuals (RGR) prior to feeds
Number of subjects: 61
Study 25166623 — intervention group
Group type: COMPARATOR
Intervention: No routine evaluation of gastric residuals (Control)
Number of subjects: 61
Study 23145973 — intervention group
Group type: EXPERIMENTAL
Intervention: High fluoride (≥2 ppm) and heavy force (225 g)
Number of subjects: 48
Study 23145973 — intervention group
Group type: COMPARATOR
Intervention: Low fluoride (≤0.05 ppm) and heavy force (225 g)
Number of subjects: 48
Study 23145973 — intervention group
Group type: EXPERIMENTAL
Intervention: High fluoride (≥2 ppm) and light force (25 g)
Number of subjects: 48
Study 23145973 — intervention group
Group type: COMPARATOR
Intervention: Low fluoride (≤0.05 ppm) and light force (25 g)
Number of subjects: 48
Study 20847092 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily administration of maintenance prednisolone for 7 days during intercurrent infections
Number of subjects: 100
Study 20847092 — intervention group
Group type: COMPARATOR
Intervention: Alternate-day prednisolone
Number of subjects: 100
Study 19650876 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin detemir (660 mU/kg, infusion rate 5 mU/kg/min)
Number of subjects: 12
Study 19650876 — intervention group
Group type: COMPARATOR
Intervention: Human insulin (60 mU/kg, infusion rate 2 mU/kg/min)
Number of subjects: 12
Study 19650876 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin detemir
Number of subjects: 12
Study 19650876 — intervention group
Group type: COMPARATOR
Intervention: Human insulin
Number of subjects: 12
Study 19650876 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin detemir and Human insulin
Number of subjects: 12
Study 21444871 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus cisplatin chemoradiotherapy followed by brachytherapy and adjuvant gemcitabine/cisplatin chemotherapy
Number of subjects: 515
Study 21444871 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin and concurrent XRT followed by BCT only
Number of subjects: 515
Study 16054887 — intervention group
Group type: EXPERIMENTAL
Intervention: HD-HSA (Human serum albumin from hemodialysis patients)
Number of subjects: 20
Study 16054887 — intervention group
Group type: COMPARATOR
Intervention: Normal-HSA (Human serum albumin from healthy subjects)
Number of subjects: 20
Study 12406842 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Number of subjects: 14
Study 12406842 — intervention group
Group type: COMPARATOR
Intervention: Sham training
Number of subjects: 14
Study 9620099 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate 1 g every 6 hours
Number of subjects: 53
Study 9620099 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 300 mg by intravenous bolus every 8 hours
Number of subjects: 53
Study 9620099 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 900 mg by continuous intravenous infusion/24 hours
Number of subjects: 53
Study 7609574 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-8
Number of subjects: 12
Study 7609574 — intervention group
Group type: EXPERIMENTAL
Intervention: Monocyte chemoattractant factor
Number of subjects: 12
Study 2693929 — intervention group
Group type: EXPERIMENTAL
Intervention: Letosteine (25 mg x 3 g/die for 10 days)
Number of subjects: 40
Study 2693929 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 348546 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (N) 10 mg, oral
Number of subjects: 8
Study 348546 — intervention group
Group type: EXPERIMENTAL
Intervention: N + isosorbide dinitrate (ISDN) 10 mg oral
Number of subjects: 8
Study 348546 — intervention group
Group type: EXPERIMENTAL
Intervention: N + propranolol (Pr) 40 mg, oral
Number of subjects: 8
Study 348546 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 80 mg oral
Number of subjects: 8
Study 348546 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31474462 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-nutritive sucking (NNS) using a silicone pacifier 120 seconds before, during, and 120 seconds after heel prick
Number of subjects: 42
Study 29499289 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid injection + 12 weeks of exercise therapy
Number of subjects: 50
Study 29499289 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection + 12 weeks of exercise therapy
Number of subjects: 50
Study 27991432 — intervention group
Group type: EXPERIMENTAL
Intervention: omeprazole/esomeprazole (strong CYP2C19 inhibitors)
Number of subjects: 54
Study 27991432 — intervention group
Group type: COMPARATOR
Intervention: pantoprazole/rabeprazole (weak CYP2C19 inhibitors)
Number of subjects: 54
Study 24809838 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ketamine infusion
Number of subjects: 54
Study 24809838 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 54
Study 24041307 — intervention group
Group type: EXPERIMENTAL
Intervention: D7N mutation of Aβ40 and Aβ42 peptides
Number of subjects: 0
Study 19933908 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorinostat (400 mg by mouth daily) with carboplatin (6 mg/mL x min) and paclitaxel (200 mg/m2 on day 3)
Number of subjects: 94
Study 19933908 — intervention group
Group type: COMPARATOR
Intervention: Placebo with carboplatin (6 mg/mL x min) and paclitaxel (200 mg/m2 on day 3)
Number of subjects: 94
Study 19933908 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorinostat (400 mg by mouth daily) with carboplatin and paclitaxel
Number of subjects: 94
Study 19933908 — intervention group
Group type: COMPARATOR
Intervention: Placebo with carboplatin and paclitaxel
Number of subjects: 94
Study 19933908 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorinostat (400 mg by mouth daily)
Number of subjects: 94
Study 19933908 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 18403184 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton magnetic resonance spectroscopy (MRS)
Number of subjects: 36
Study 18403184 — intervention group
Group type: COMPARATOR
Intervention: Control group (N=48)
Number of subjects: 36
Study 16153271 — intervention group
Group type: EXPERIMENTAL
Intervention: Bradykinin (BK) 5 microg/mL infusion
Number of subjects: 16
Study 16153271 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 16
Study 12514672 — intervention group
Group type: EXPERIMENTAL
Intervention: Conivaptan (vasopressin antagonist)
Number of subjects: 0
Study 12514672 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10962771 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily maintenance doses every 24 hours (4 or 8 mg/70 kg)
Number of subjects: 14
Study 10962771 — intervention group
Group type: EXPERIMENTAL
Intervention: Double the daily maintenance dose every 48 hours (8 or 16 mg/70 kg)
Number of subjects: 14
Study 10962771 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple the daily maintenance dose every 72 hours (12 or 24 mg/70 kg)
Number of subjects: 14
Study 10962771 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadruple the daily maintenance dose every 96 hours (16 or 32 mg/70 kg)
Number of subjects: 14
Study 10962771 — intervention group
Group type: COMPARATOR
Intervention: Daily dosing regimen
Number of subjects: 14
Study 8553952 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. administration of ultrasmall superparamagnetic iron oxide (USPIO) particle (Code 7227)
Number of subjects: 27
Study 8553952 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat-suppressed T1-weighted imaging
Number of subjects: 27
Study 1985710 — intervention group
Group type: EXPERIMENTAL
Intervention: Protracted infusional 5-fluorouracil (5-FU) infusion at 300 mg/m2/d for 10 weeks of every 12 weeks
Number of subjects: 184
Study 1985710 — intervention group
Group type: COMPARATOR
Intervention: Protracted infusional 5-fluorouracil (5-FU) infusion with weekly cisplatin (20 mg/m2)
Number of subjects: 184
Study 1985710 — intervention group
Group type: EXPERIMENTAL
Intervention: Protracted infusional 5-fluorouracil (5-FU) infusion
Number of subjects: 184
Study 1985710 — intervention group
Group type: COMPARATOR
Intervention: Protracted infusional 5-fluorouracil (5-FU) infusion with weekly cisplatin
Number of subjects: 184
Study 7104464 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid diet
Number of subjects: 5
Study 7104464 — intervention group
Group type: COMPARATOR
Intervention: Fasting diet
Number of subjects: 5
Study 7104464 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate diet
Number of subjects: 5
Study 31599775 — intervention group
Group type: EXPERIMENTAL
Intervention: High-density spectral domain optical coherence tomography (SD-OCT) optic nerve volume scans
Number of subjects: 256
Study 30203752 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical paravertebral nerve block combined with Mailuoning and Angelica sinensis injection
Number of subjects: 120
Study 30203752 — intervention group
Group type: COMPARATOR
Intervention: Glucocorticoid nerve block therapy
Number of subjects: 120
Study 26786823 — intervention group
Group type: COMPARATOR
Intervention: Handling money (market-mode cue)
Number of subjects: 0
Study 23807029 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilizing knee brace for 6 weeks post-operatively
Number of subjects: 64
Study 23807029 — intervention group
Group type: COMPARATOR
Intervention: No stabilizing knee brace for 6 weeks post-operatively
Number of subjects: 64
Study 23062767 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg
Number of subjects: 60